Differences among Bank of Canada, the Bank of England, and the Bank of Essay

Differences among Bank of Canada, the Bank of England, and the Bank of Japan - Essay Example In 1694, the bank operated from its foundation, and it was privately owned. However, the bank has since become independent becoming a public organization. The Treasury Solicitor owns the bank on behalf of the Government. In addition, the Treasury Solicitor has independence in monetary policy (Yasin, 2013). The bank of Japan, BOJ had its reorganization after the post-war time in 1942. The bank was independent and operated independently. The BOJ had its own monetary and controlled its credits. The bank had considerable independence that lead to losing of its accountability leading to promulgation of the Japan law. The BOJ controlled the monetary and currency, which controlled the economy. The government maintains a close relationship with the bank. The government helps the bank in managing the currency and monetary aspects of the bank (Yasin, 2013). The main difference among the three banks is the ownership and control of the banks. The Canada Minister of Finance owns the bank of Canada. He owns the bank behalf of Her Majesty in right. The Treasury Solicitor on behalf of the Government owns the Bank of England. The Bank of Japan is independently owned, and the government maintains a close relationship to help the bank in its currency and monetary aspect (Yasin,

Gene Therapy Essay Example | Topics and Well Written Essays - 1250 words

Gene Therapy - Essay Example Gene therapy uses a vector which functions to deliver DNA inside body cells after packaging. The DNA, once in the body through the vector goes into the bloodstream then into cells and finally is incorporated into a chromosome. However, naked DNA approaches have been considered too more so in the field of vaccine development. Once embedded in the patient’s system, the DNA is expressed by the cell machinery, leading to the production of therapeutic protein which corrects the patient’s condition. Emphasis lies on administering a gene that will cause a protein to be expressed and that the patient specifically needs. In addition, with the advances in knowledge of nuclease functions in humans, there have begun explorations into ways of incorporating genes that encode nucleases into chromosomes. The expressed nucleases then disrupt the genes causing the disease by ‘editing’ the chromosome (Giacca, 2010). The concept of gene therapy was first thought possible in 1972 but caution was implored especially concerning its application/ experimentation on humans. In 1990, however, Ashanti DeSilva became the first recipient of gene therapy treatment in the United States for ADA-SCID. Early skepticisms arose with several initial clinical failures with many regarding gene therapy as an over-rated procedure but successes since 2006 have seen many regain their faith in this new form of treatment. Over 2,000 recorded clinical trials have so far been performed on humans. These include successful treatment of diseases such as multiple myeloma, Parkinson’s disease, Leber’s congenital amaurosis, adrenoleukodystrophy, hemophilia, ADA-SCID, chronic lymphocytic leukemia and acute lymphocytic leukemia. With such successes, many governments and companies (especially research institutions) have continued to invest even more on gene therapy. Recently, Glybera became the first gene therapy proc edure to be embraced in Europe and the